LA JOLLA, Calif., Oct. 18, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it received notice from The Nasdaq Stock Market LLC "NASDAQ" indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5450(a)(1) (the "Bid Price Rule") for continued listing on The NASDAQ Global Market. Accordingly, the Company has regained compliance with the Bid Price Rule and NASDAQ considers the matter closed.
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in La Jolla, CA. For more information, please visit http://www.regulusrx.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/regulus-regains-compliance-with-nasdaq-listing-requirements-300733953.html
SOURCE Regulus Therapeutics Inc.
Investor Relations Contact: Dan Chevallard, Chief Financial Officer, 858-202-6376, email@example.com